

Market Announcement

25 September 2025

Invex Therapeutics Limited (ASX: IXC) – Suspension from Quotation

The securities of Invex Therapeutics Limited ('IXC') will be suspended from quotation immediately under Listing Rule 17.2 at the request of IXC, pending the release of an announcement by IXC.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in IXC's request for voluntary suspension; or
- the release of the announcement to the market.

IXC's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance



25 September 2025

Ms Barbara Lim
Senior Adviser, Listings Compliance (Perth)
ASX Compliance Pty Ltd
Level 40, Central Park, 152 -158 St Georges Terrace
PERTH WA 6000

By Email: barbara.lim@asx.com.au; ListingsCompliancePerth@asx.com.au

Dear Barbara

Request for Voluntary Suspension

Invex Therapeutics Limited (ACN 632 145 334) (the **Company**) requests a voluntary suspension to the trading of its securities, with effect from commencement of trading on Thursday, 25 September 2025.

In accordance with ASX Listing Rule 17.2, the Company provides the following information:

1. The voluntary suspension is requested pending an announcement to be made by the Company regarding a material acquisition, and the Company providing responses to a price query from ASX.
2. At this stage the Company expects the voluntary suspension to remain in place until the earlier of the Company making the material announcement, and commencement of trading on Monday 29 September 2025.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the voluntary suspension.

Yours sincerely

On behalf of the Board of Invex Therapeutics Limited

Narelle Warren
Company Secretary